^
    3d
    SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    zeprumetostat (SHR-2554)
    6d
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    7d
    A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=22, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    10d
    Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture. (PubMed, Int J Mol Sci)
    Notably, NGS and digital droplet PCR confirmed a TP53 frameshift mutation (c.902del; p.Pro301Glnfs*44) with a fractional abundance of 0.31% in the lymph node and a (c.742C>T; p.Arg248Trp) mutation (0.309%) in the bone marrow. Results underscore the importance of NGS-based clonality to diagnose NMZL with prominent PD1+ T-cell hyperplasia, and prompt further investigation into tissue-specific mutational signatures in these unusual cases.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1) • IGH (Immunoglobulin Heavy Locus) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • CD4 (CD4 Molecule) • TNFRSF14 (TNF Receptor Superfamily Member 14)
    |
    TP53 mutation
    10d
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P3, N=120, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Epidaza (chidamide) • XNW5004
    10d
    Revealing tumor microenvironmental heterogeneity and prognostic value in angioimmunoblastic T-cell lymphoma via spatial transcriptome sequencing. (PubMed, Cell Death Dis)
    Collectively, our findings illuminate the heterogeneity and prognostic implications of the TME in AITL, providing a robust foundation for the rational design of targeted immunotherapeutic approaches. These insights may substantially advance the development of personalized treatment strategies for AITL patients.
    Journal
    |
    PD-1 (Programmed cell death 1) • CD40 (CD40 Molecule) • CD40LG (CD40 ligand)
    11d
    Primary central nervous system T-cell lymphoma: a single-centre retrospective study and literature review. (PubMed, BMJ Neurol Open)
    Histopathological examination typically reveals prominent perivascular lymphocytic cuffing in PCNSTL. CSF flow cytometry could be considered a preferred method for a definite diagnosis of PCNSTL when brain biopsy is not possible.
    Retrospective data • Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    14d
    TOUCH: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=56, Terminated, Antengene Corporation | Active, not recruiting --> Terminated; Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study
    Trial termination
    |
    carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • ifosfamide • oxaliplatin • etoposide IV • Xpovio (selinexor)
    17d
    PTCL-SEQ: Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P=N/A, N=45, Active, not recruiting, Centre Henri Becquerel | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Circulating tumor DNA
    18d
    Indolent T-cell lymphoma of the gastrointestinal tract coexisting with gastric signet-ring cell carcinoma: A case report and review of literature. (PubMed, World J Gastroenterol)
    Clinicians and pathologists must integrate assessment of these rare cases to prevent misdiagnosis and guide clinical practice.
    Review • Journal
    |
    CD8 (cluster of differentiation 8)
    19d
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=101, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    21d
    Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    MEDI-570